Pet Drug Reports

Drugs by active ingredient

Drug · single active ingredient

Diltiazem: adverse event reports

All products with this active ingredient · not in an FDA-approved animal drug

51reports naming this ingredient, 2004–20260% of all reports · about 2 a year
11reports, 12 months to March 202612 in the 12 months before
52%classed serious, as reportedof 50 reports stating it
25.5%record death or euthanasia, as reported13 reports
64.7%of reports concern dogs0% of all dog reports

FDA has received 51 adverse event reports in which a drug is recorded with diltiazem as its active ingredient, from March 2004 to February 2026. It is not the active ingredient of an FDA-approved animal drug; it reaches animals through human-label or compounded products.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 11 reports named it, close to the 12 of the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 2 reports a year and 0% of all 1,357,245 reports (0% of all dog reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

The most frequently coded terms are death (15.7%), death by euthanasia (11.8%) and lack of efficacy - NOS (11.8%). A report can list several signs, so shares add to more than 100%; 144 different terms appear across these reports.

64.7% of reports concern dogs. Not every report describes illness: 11.8% were filed wholly or partly as lack of expected effectiveness. Of reports that state seriousness, 52% were classed as serious, and 25.5% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog19 · peak 3
Mar 2024: 1Oct 2024: 2Nov 2024: 1Dec 2024: 1Jan 2025: 1Feb 2025: 1Mar 2025: 3Apr 2025: 1May 2025: 1Jun 2025: 1Jul 2025: 1Sep 2025: 1Nov 2025: 1Jan 2026: 2Feb 2026: 12022202320242025
Cat6 · peak 2
Mar 2023: 1Jun 2023: 1Jun 2024: 1Sep 2024: 1Dec 2025: 22022202320242025
Horse0 · peak 1
2022202320242025
Other3 · peak 1
Apr 2021: 1Apr 2023: 1Apr 2024: 12022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

07132004: 120042012: 120122013: 520132014: 220142015: 120152016: 120162017: 420172018: 320182019: 120192020: 320202021: 220212023: 320232024: 820242025: 1320252026: 32026

2026 covers reports received through March 2026 only.

Signs listed in reports

share of diltiazem reports listing the termall dog reports

  1. Death15.7%8
  2. Death by euthanasia[the animal was euthanized]11.8%6
  3. Lack of efficacy - NOS[the product did not have the expected effect]11.8%6
  4. Lethargy[unusually tired or inactive]11.8%6
  5. Vomiting11.8%6
  6. Anorexia[not eating]9.8%5
  7. Accidental exposure[exposure that was not intended]7.8%4
  8. Diarrhoea[diarrhea]7.8%4
  9. Tachycardia[fast heart rate]7.8%4
  10. Abnormal electrocardiogram (ECG)5.9%3
  11. Anaemia NOS[low red blood cell count]5.9%3
  12. Atrial fibrillation5.9%3
  13. Azotaemia[raised kidney values in blood]5.9%3
  14. Bladder distension5.9%3
  15. Crying5.9%3
  16. Hypoalbuminaemia[low blood albumin]5.9%3
  17. Musculoskeletal disorder NOS[NOS: not otherwise specified]5.9%3
  18. Pain NOS[NOS: not otherwise specified]5.9%3

Top 30 of 144 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal27.5%14
Recovered with Sequela2%1
Ongoing27.5%14
Died17.6%9
Euthanized11.8%6
Outcome Unknown19.6%10

What kind of report it was

Safety issue88.2%45
Lack of expected effectiveness2%1
Both safety and lack of expected effectiveness9.8%5
Manufacturing or product defect0%0
Other0%0

Coloured bar: reports naming diltiazem. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Dog64.7%33
Cat19.6%10
Human exposure15.7%8

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year2%1
1 to 3 years9.8%5
4 to 7 years3.9%2
8 to 11 years25.5%13
12 years and over52.9%27
Age not given5.9%3

Weight of the animal

Under 5 kg (11 lb)13.7%7
5 to 9.9 kg (11–22 lb)7.8%4
10 to 24.9 kg (22–55 lb)21.6%11
25 to 44.9 kg (55–99 lb)25.5%13
45 kg and over (99 lb+)21.6%11
Weight not given9.8%5

Route of administration stated in reports: oral (22).

In context

MeasureDiltiazemAll dog reportsAll reports
Reports51985,6751,357,245
Share of that pool's reports naming this drug—0%0%
Classed serious, of reports stating it52%38.3%38.6%
Death or euthanasia recorded, per 1,000 reports254.95563.8
Filed as lack of expected effectiveness (wholly or partly)11.8%—23%
Top term, share of reportsDeath 15.7%2.9%—

This set accounts for 100% of all reports naming diltiazem, so no separate ingredient column is shown. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

FDA-approved products (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

The Green Book lists no approved animal drug with these ingredients. Reports reach FDA for human-label and compounded drugs that veterinarians prescribe.

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about diltiazem reports

How many adverse event reports has FDA received for diltiazem?

51 reports record a drug with diltiazem as its active ingredient in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 11 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

What signs are reported most often?

death (15.7%), death by euthanasia (11.8%), lack of efficacy - NOS (11.8%), lethargy (11.8%) and vomiting (11.8%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

dog (64.7%), cat (19.6%) and human exposure (15.7%). Among single-breed animals the most frequent labels are Domestic Shorthair, Labrador Retriever, Saint Bernard Dog and Devon Rex; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

11 reports in the 12 months to March 2026, close to the 12 of the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that diltiazem harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of diltiazem?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.